1. Introduction {#sec1-jcm-08-00639}
===============

Gastric cancer (GC) is one of the most common malignant tumors and is associated with multiple genetic mutations and environmental interactions \[[@B1-jcm-08-00639],[@B2-jcm-08-00639]\]. While in recent years several combinations of chemotherapy regimens have been tried, the improvement in survival rates is modest \[[@B3-jcm-08-00639]\]. Indeed, GC still remains the third most common cause of cancer-related mortality \[[@B4-jcm-08-00639],[@B5-jcm-08-00639]\].

As demonstrated by several studies, GC is characterized by a considerable heterogeneity at molecular, histological, and phenotypic levels \[[@B6-jcm-08-00639]\], which plays a pivotal role in therapy resistance thus tumor recurrence \[[@B7-jcm-08-00639],[@B8-jcm-08-00639]\].

The cancer stem cell (CSC) model of tumor progression theorizes that a small subpopulation of self-renewing cancer cells within tumor can sustain neoplasm growth and metastases spread \[[@B9-jcm-08-00639],[@B10-jcm-08-00639]\], as well as cancer relapse and resistance to chemotherapy \[[@B11-jcm-08-00639]\]. In CSCs, many of the normal stem cells properties, including self-renewal, differentiation, and proliferative potential, are dysregulated, principally due to epigenetic changes and genetic mutations \[[@B12-jcm-08-00639]\].

The first evidence for a role of stem cells in cancer arose from the work of Lapidot et al., which reported that a small subpopulation of cells was able to reproduce leukemic disease in immunodeficient mice \[[@B13-jcm-08-00639]\]. Since this finding, more and more studies have suggested the existence of CSCs in numerous solid tumors \[[@B14-jcm-08-00639],[@B15-jcm-08-00639],[@B16-jcm-08-00639],[@B17-jcm-08-00639],[@B18-jcm-08-00639]\], including GC \[[@B19-jcm-08-00639],[@B20-jcm-08-00639]\].

One of the most difficult challenges to target CSCs is to identify specific markers and, at the same time, to uncover targetable molecular features associated with their phenotype. To date, the molecular characterization of CSCs remains largely unknown.

Recent studies highlight the role of several microRNAs (miRNAs) as key regulators of molecular mechanisms that are associated with cancer drug resistance, making them an attractive therapeutic target \[[@B21-jcm-08-00639]\]. According to recent theories that support the origin of cancer from CSCs, many studies suggest that miRNA dysregulation in CSCs may be involved in tumor growth and spread \[[@B22-jcm-08-00639]\].

The miRNAs are categorized as a novel class of non-coding, single-strand, small RNAs. Based on their length, non-coding RNAs are classified in two groups: those with less than 200 nucleotides (smallRNAs), and those with more than 200 nucleotides, e.g., long non-coding RNAs (lncRNAs) and long intergenic non-coding RNAs (lincRNAs) \[[@B22-jcm-08-00639]\]. The miRNAs are 21--25 nucleotides long, acting as post-transcriptional regulators through their binding at the untranslated region (mainly 3'-UTR (untranslated region)), of specific messenger RNAs (mRNAs), targeting their degradation or translation inhibition \[[@B23-jcm-08-00639],[@B24-jcm-08-00639],[@B25-jcm-08-00639]\]. The first two miRNAs, lin-4 and let-7, were discovered in *Caenorhabditis elegans* \[[@B26-jcm-08-00639]\]. Since their discovery, miRNAs were shown to play a specific role in the regulation of embryogenesis, stem/progenitor cells and CSCs biology \[[@B27-jcm-08-00639]\]. Here, we review recent reports, indicating the key role of miRNAs in regulating CSCs, with a specific focus on gastric cancer stem cells (GCSCs), and we also report the results of a meta-analysis aimed at predicting a novel miRNA signature starting from GCSC global gene expression profiles.

2. MicroRNAs and Cancer Stem Cells {#sec2-jcm-08-00639}
==================================

In this section we will discuss recent reports about relationship between miRNAs and cancer stem cells in different types of tumors (summarized in [Table 1](#jcm-08-00639-t001){ref-type="table"}).

In 2003 CSCs from breast cancer (BCSCs) were identified \[[@B13-jcm-08-00639]\], and in 2007 Yu and colleagues identified let-7 which, by targeting *RAS* and *HMGA2* genes, is a master regulator for breast CSC properties, including self-renewal and multipotent differentiation capabilities \[[@B28-jcm-08-00639]\]. Since then, several studies have confirmed the regulative role of miRNAs in the stem-like properties of BCSCs \[[@B29-jcm-08-00639],[@B30-jcm-08-00639],[@B31-jcm-08-00639],[@B32-jcm-08-00639],[@B33-jcm-08-00639]\].

With respect to hematological malignancies, several abnormally regulated miRNAs were identified which target genes implicated in self-renewal, transformation, proliferation, and tumorigenicity \[[@B34-jcm-08-00639],[@B35-jcm-08-00639],[@B36-jcm-08-00639],[@B37-jcm-08-00639]\]. Of note, miR-22 and miR-99, are oncogenic miRNAs which promote stem cell self-renewal \[[@B34-jcm-08-00639],[@B35-jcm-08-00639]\]. Recently, Lechman et al. showed that miR-126 targeting the *PI3K/AKT/mTOR* pathway controls the cell cycle progression of leukemia stem cells (LSC) \[[@B36-jcm-08-00639]\].

Numerous studies have also highlighted the important role of miRNAs in determining glioblastoma stem-like cells (GSCs) biological features \[[@B38-jcm-08-00639],[@B39-jcm-08-00639],[@B40-jcm-08-00639],[@B41-jcm-08-00639]\]. In particular, miR-34a directly inhibits *c-Met* and *Notch-1/2* in glioma cells and stem cells through direct 3′-UTR binding \[[@B42-jcm-08-00639]\]. Other miRNAs involved in the regulation of glioma cells stemness are: miR-125b and miR-29b \[[@B43-jcm-08-00639],[@B44-jcm-08-00639]\].

In 2007, Ma et al. identified and isolated, for the first time, CSCs in liver cancer (LCSCs) \[[@B45-jcm-08-00639]\]. To date, several miRNAs were reported to modulate self-renewal, proliferation, apoptosis, migration, invasion, and differentiation in LCSCs \[[@B46-jcm-08-00639],[@B47-jcm-08-00639]\]. In particular, many studies underline the role of the let-7 family, miR-217 and miR-452 in the Wnt signaling pathway \[[@B48-jcm-08-00639],[@B49-jcm-08-00639],[@B50-jcm-08-00639],[@B51-jcm-08-00639]\].

The miR-200 family, miR-203, miR-137, miR-34a, and miR-221, targeting various genes involved in the regulation of CSC properties, are considered to be the regulators of stem cell properties in colorectal CSCs \[[@B52-jcm-08-00639]\]. A recent study reported that miR-508 is negatively correlated with the stem-like/mesenchymal colorectal cancer (CRC) subtype \[[@B53-jcm-08-00639]\].

Fang et al. in 2015 identified, in prostate cancer stem cells (PCSCs), different miRNAs involved in the regulation of specific stemness-related surface markers and transcription factors \[[@B54-jcm-08-00639]\]. Prostate tumor growth and metastasis formation capability are suppressed in PCSCs by miR-141, which targets genes such as *CD44*, *EZH2*, and *Rho GTPases* \[[@B55-jcm-08-00639]\].

3. Gastric Cancer Stem Cells {#sec3-jcm-08-00639}
============================

There are two main hypotheses about the origin of GCSCs: the first one suggests that GCSCs derived from mutations of gastric stem cells (GSCs) which lead to sequential transformation of normal gastric mucosa to atrophic gastritis, intestinal metaplasia, atypical hyperplasia, and finally to GC \[[@B58-jcm-08-00639]\]. Based on this hypothesis, it is crucial to evaluate the phenotypes of GCSCs in distinct anatomical regions and expressing different specific markers. In particular, the Lgr5^+^ subpopulation resides at the base of the pyloric glands, Villin^+^ cells are located at the bottom of antropyloric glands, Troy-expressing cells are located at the base of the corpus gastric glands, and Mist1^+^ and Sox2^+^ cells reside at the base of both corpus--fundus and antrum--pylorus regions and in the isthmus \[[@B59-jcm-08-00639]\].

The second hypothesis is based on recent studies suggesting that bone marrow-derived cells (BMDCs) are candidates for GCSC \[[@B58-jcm-08-00639]\]. In particular, Houghton et al. reported that, in mice with persistent *Helicobacter* infection, BMDCs migrate to the gastric mucosa and undergo malignant transformation into cancerous epithelial cells \[[@B60-jcm-08-00639]\]. In 2012, Varon et al. confirmed that long-term *Helicobacter pylori* infection induces the recruitment and accumulation of BMDCs in the gastric epithelial mucosa, participating in GC progression \[[@B61-jcm-08-00639]\]. In 2016, Zhang and colleagues supported this hypothesis \[[@B62-jcm-08-00639]\].

CSCs can be isolated through fluorescence-activated cell sorting (FACS) and magnetic cell sorting (MACS), exploiting the presence of CSCs specific markers, as well as stem cell side population (SP) analysis \[[@B63-jcm-08-00639],[@B64-jcm-08-00639],[@B65-jcm-08-00639]\]. About the different methods typically used to characterize CSCs, two phenotypic assays proved to be the most exhaustive. One is the in vitro "spheroid colony formation", and the second is in vivo "tumorigenicity capability" through mouse model xenotransplantation \[[@B66-jcm-08-00639],[@B67-jcm-08-00639]\]. In [Table 2](#jcm-08-00639-t002){ref-type="table"}, we have listed the major surface markers or their combinations currently used to identify GCSCs able to generate both in vitro spheroid colonies and in vivo tumors.

4. MicroRNAs and Gastric Cancer Stem Cells {#sec4-jcm-08-00639}
==========================================

The expression of miRNAs has a pivotal role in the maintenance of stem/progenitor cells. Its perturbation is causative of the altered balance between self-renewal and differentiation that may cause a tumorigenic cellular phenotype \[[@B79-jcm-08-00639]\]. Despite the considerable advances made in understanding the role of miRNAs in regulating GCSC biology, the mechanisms of action and the clinical utility of these regulatory RNA molecules are still far from being fully elucidated.

In 2017, Zeng et al. demonstrated, for the first time, that miR-145 inhibits the stem-like properties of GC targeting directly CD44 observing, at the same time, that the overexpression of miR-145 in GC was correlated with chemoresistance \[[@B80-jcm-08-00639]\]. Furthermore, the miR-711 downregulated the CD44 expression causing the inhibition of epithelial to mesenchymal transition (EMT) in GC cells both in vitro and in vivo \[[@B81-jcm-08-00639]\]. Moreover, in a recent study, Lee and colleagues underlined a relationship between the upregulation of miR-193a-3p and cisplatin resistance in CD44^+^ GC cells \[[@B82-jcm-08-00639]\]. Functional studies have also shown that CD44^+^ cells exhibit a much more pronounced sphere-forming activity than CD44^-^ cells. A miRNA microarray analysis displayed that miR-196a-5p was upregulated in CD44^+^ cells and its suppression led to decreased colony formation and invasion of GCSCs suggesting a significant role of miR-196a-5p in EMT and invasion by targeting Smad4 in GCSCs \[[@B83-jcm-08-00639]\]. Furthermore, in a recent study, Shao et al. reported that overexpression of lenti-miRNA-19b/20a/92a significantly enhanced the ability of GCSCs in forming tumor spheres \[[@B84-jcm-08-00639]\].

Several signaling pathways shown to cooperatively ensure stem cell homeostasis are finely regulated. Abnormalities in their regulation may be responsible for the self-renewal unbalance of GCSCs \[[@B85-jcm-08-00639]\]. However, it is well known that several specific miRNAs target genes related to key signal pathways involved in stemness regulation, such as Notch, Wnt/β-catenin, transforming growth factor-beta (TGF-β)/Smad, and Hippo signaling pathways.

Precisely, an investigation conducted by Xiao et al., demonstrated that miR-124 targeting *JAG1* suppress the Notch signaling pathway inhibiting invasion, migration, and proliferation of GC cells. \[[@B86-jcm-08-00639]\].

Wu et al reported that miR-17-92, activates Wnt/β-catenin signaling, by targeting *E2F1* and *HIPK1* \[[@B87-jcm-08-00639]\]. Another study suggested that miR-501-5p constitutively activates Wnt/β-catenin signaling by targeting *DKK1*, *NKD1*, and *GSK3β*, promoting a GCS-like phenotype \[[@B88-jcm-08-00639]\]. According to these studies, a recent study proposed miRNA-194 as oncogene that promotes GC cell proliferation and migration by activating Wnt signaling and acting on the negative Wnt regulator SUFU (suppressor of fused homolog) \[[@B89-jcm-08-00639]\].

In addition, Shao et al. in 2018, affirmed that miRNA-19b/20a/92a promotes GCSC self-renewal by targeting *E2F1* and *HIPK1* and activating the β-catenin signaling pathway \[[@B84-jcm-08-00639]\].

In the same year, Song et al. proposed miR-338 as a putative tumor suppressor in GC which targeting *EphA2* blocks EMT leading to inhibition of Wnt/β-catenin signaling \[[@B90-jcm-08-00639]\].

In 2014 Yu et al. displayed that miR-106b family expression modulated cancer stem-like cell properties, in particular EMT, via TGF-β/Smad signaling pathway in CD44^+^ stem-like cells \[[@B91-jcm-08-00639]\]. Recent studies support the role of miRNAs in the regulation of Hippo pathway. First Li et al. reported that miR-93-5p promotes GC-cell progression through the inactivation of the Hippo signaling pathway \[[@B92-jcm-08-00639]\]. Later in 2018, Kang and colleagues demonstrated the involvement of miR-375 in this pathway by targeting *YAP1/TEAD4-CTGF* axis in gastric tumorigenesis \[[@B93-jcm-08-00639]\].

5. Meta-Analysis of Up/Down miRNAs in GCSCs Features: A Focus on Stemness-Related Pathways {#sec5-jcm-08-00639}
==========================================================================================

In this section, we illustrate the results of a meta-analysis performed by using public microarray datasets to obtain a novel miRNA signature from genes resulted differentially expressed between GC cells and GCSCs. In particular, following PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines ([Figure S1](#app1-jcm-08-00639){ref-type="app"}), we selected data from two public datasets: GSE112631 (Illumina) and GSE20058 (Affymetrix). The first one, consisting of 12 samples, refers to gene expression data of CD133^+^ and CD133^−^ cells sorted from three GC cell lines (KATO-III, SNU216, and SNU601) \[[@B94-jcm-08-00639]\].

The second dataset, consisting of four samples (resulting from a quality check on the original eight samples), characterizes the expression of stem cell side population (SP) of AGS cell line \[[@B95-jcm-08-00639]\]. Briefly, after normalization performed accordingly to gene expression technologies (neqc and RMA), we used linear models and the empirical Bayes statistics by limma package \[[@B96-jcm-08-00639]\] to assess differential gene expression data.

To perform meta-analysis, we combined *p*-values by Fisher's sum of logs method by the metap package, followed by FDR multiple testing correction. Two significant (adjusted *p*-value \< 0.05) differentially expressed genes (DEGs) lists were produced: a list of genes significantly highly expressed in GCSCs and a list of genes significantly highly expressed in GC cells. An enrichment analysis carried out using the clusterProfiler package \[[@B97-jcm-08-00639]\], focused on miRNA targets (MSigDB collection \[[@B98-jcm-08-00639],[@B99-jcm-08-00639]\]), revealed the miRNA were bona fide differentially expressed between the two conditions. We obtained eight (adjusted *p*-value \< 0.05) predicted downregulated miRNAs ([Table 3](#jcm-08-00639-t003){ref-type="table"}) from DEGs highly expressed in GCSCs and four (*p*-value \< 0.05) predicted upregulated miRNAs ([Table 4](#jcm-08-00639-t004){ref-type="table"}).

Interestingly, among the predicted miRNAs, which we hypothesized to have a key role in the GCSCs biology, we found several miRNAs previously identified \[[@B79-jcm-08-00639],[@B111-jcm-08-00639]\].

In particular, in 2014 Liu et al. evaluated the miRNA expression profiles in spheroid body-forming cells and parental cells (MKN-45), finding182 miRNAs differentially expressed.

In conformity with the data obtained by Liu and colleagues, with respect to the downregulated predicted miRNAs we recovered miR-193A, miR-193B, and miR-93 \[[@B111-jcm-08-00639]\].

Later, in 2017 Golestanech et al, studied the differentially expressed miRNAs in CSCs and cancer cells of the GC cell line MKN-45. According to their data, we identified, in the predicted miRNAs, an increase in miR-302 expression level and a downregulation of miR-372, miR-373 and miR-520C-5p in CSCs compared to in cancer cells \[[@B79-jcm-08-00639]\].

Subsequently, we extended the enrichment analysis by DIANA-mirPath 3.0 \[[@B113-jcm-08-00639]\] web server. Briefly, for each miRNA (both 5′ and 3′ arm), the algorithm retrieves the putative regulated genes and uses them to calculate the activation of each KEGG (kyoto encyclopedia of genes and genomes) pathway ([Tables S1 and S2](#app1-jcm-08-00639){ref-type="app"}).

The [Figure 1](#jcm-08-00639-f001){ref-type="fig"} and [Figure 2](#jcm-08-00639-f002){ref-type="fig"} depict the heat maps of significant miRNAs and the relative KEGG activated pathways. All the analyses were performed by R/Bioconductor \[[@B114-jcm-08-00639],[@B115-jcm-08-00639]\].

We focused our attention on the enrichment of the two stemness-related pathways, whose involvement in the genesis of GCSCs has long been established: Transforming growth factor-β (TGF-β) and Hippo signaling pathways.

*TGF-β* has emerged as key regulator of stem cell self-renewal and differentiation \[[@B116-jcm-08-00639]\]. A recent study suggests the putative oncogenic function of TGF-β in GC considering that its overexpression in the extracellular matrix (ECM) induces tumorigenicity \[[@B117-jcm-08-00639]\]. Other evidence underlines that *H. pylori* infection might promote the TGF-β1-induced EMT in gastric mucosa and the development of GCSCs \[[@B118-jcm-08-00639]\]. Moreover, bone marrow-derived mesenchymal stem cells (BM-MSCs) were shown to provide advantageous microenvironments for cancer progression by supporting proliferation, cluster formation, expansion of the CD133^+^ population, upregulation of *TGFβ1* and *WNT5A* genes in co-cultured MKN7 GC cells \[[@B119-jcm-08-00639]\]. Furthermore, BM-MSCs promote GCSCs phenotype via TGF-β signaling in response to gastritis \[[@B120-jcm-08-00639]\]. Peng et al. confirmed the role of *TGF-β/SOX4* axis in GC cells EMT and in the stemness regulation \[[@B121-jcm-08-00639]\].

The Hippo signaling pathway is known as a tumor-suppressing pathway that acts on tissue homeostasis and organ size by inhibiting cell growth, proliferation and promoting apoptosis. The deregulation of Hippo signaling pathway is associated with initiation, development and metastasis spreading also in GC \[[@B122-jcm-08-00639]\]. Moreover, Qiao et al. propose the Hippo pathway as a potential therapeutic target for GC treatment \[[@B123-jcm-08-00639]\].

[Figure 3](#jcm-08-00639-f003){ref-type="fig"} and [Figure 4](#jcm-08-00639-f004){ref-type="fig"}, processed by the pathview package \[[@B124-jcm-08-00639]\], indicate several deregulated genes involved in these pathways. Their up or down expression may be related to specific miRNAs, which may represent potential GCSC targets.

With respect to the TGF-β pathway, the down expression of *Follistatin* (*FST*) seems interesting.

*FST* is an antagonist of the TGF-β superfamily member activin, a pleiotropic growth factor involved in proliferation, cancer progression, and cell invasion \[[@B125-jcm-08-00639]\]. The roles of *FST* in tumorigenesis, progression, metastasis, and angiogenesis processes in different types of solid tumors \[[@B126-jcm-08-00639]\] are known, and therefore we may suppose that the downregulation of FST, mediated by several miRNAs, could enhance the effects of activin and promote GCSC proliferation.

New in-depth studies, in this regard, could be useful to better understand the putative role of several miRNAs as regulators of TGF-β superfamily members' antagonists and to possibly validate our hypothesis.

Among the up expressed genes involved in the Hippo signaling pathway, we hypothesize protein phosphatase 1 (PP1) to have a prominent role, as outlined below. The overexpression of *PP1* leads to dephosphorylation of *TAZ* and *YAP*. Unphosphorylated *TAZ* and *YAP* remain in the nucleus where they interact with *TEA/ATTS* domain (TEAD) transcription factors and promote cell proliferation, stem cell self-renewal, and tumorigenesis \[[@B127-jcm-08-00639]\]. In line with our hypothesis, *YAP* and *TAZ* represent primary effectors of the Hippo pathway and have been recognized as important drivers of cancer progression and metastasis \[[@B128-jcm-08-00639]\].

6. Conclusions {#sec6-jcm-08-00639}
==============

Overall, here we highlight the key role played by miRNAs in GCSC properties. Furthermore, our results indicate that other putative miRNAs partially ignored up to now should be studied. A better knowledge of miRNA molecular mechanisms and the gene targets involved in the regulation of GCSCs could open up new strategies in the target therapy of GCSCs.

However, due to the scarce availability of GCSCs global gene expression profile datasets, and the difficulties in retrieving them from open access repository miRNA GCSC datasets, the current meta-analysis is far from exhaustive. Therefore, new studies comprising integrated genes and miRNA expression data are strongly suggested.

The following are available online at <https://www.mdpi.com/2077-0383/8/5/639/s1>. Table S1: Significant KEGG pathways by predicted upregulated miRNAs; Table S2: Significant KEGG pathways by predicted downregulated miRNAs; Figure S1: PRISMA flow diagram.
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jcm-08-00639-t001_Table 1

###### 

Function of up/downregulated microRNA (miRNAs) in different types of cancer stem cells and their molecular targets.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  MiRNA(s)                   Target Gene(s)                                                                            Function                                                                        Cancer Type                  Up/Downregulated                                       Reference(s)
  -------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------ ----------------------------------------------------------------------------
  **Let-7**                  *RAS*, *HMGA2*                                                                            Regulation of self-renewal and multipotent differentiation capabilities         Breast                       Down-regulated                                         Yu et al. \[[@B28-jcm-08-00639]\]

  **MiR-200 family**         *BMI1*                                                                                    Regulator of stem cell self-renewal                                             Breast                       Down-regulated                                         Shimono et al. \[[@B29-jcm-08-00639]\]

  *Suz12*                    Inhibition of mammosphere, in combination with chemotherapy suppression of tumor growth   Breast                                                                          Down-regulated               Iliopoulos and Lindahl-Allen \[[@B30-jcm-08-00639]\]   

  *ZEB1*, *ZEB2*, *TWIST1*   Transition to a breast cancer stem cell-like state                                        Breast                                                                          Down-regulated               Lim et al. \[[@B31-jcm-08-00639]\]                     

  **MiR-30 family**          *Ubc9*, *ITGB3*, *AVEN*                                                                   Involvement in to apoptosis, proliferation and in tumor initiating BCSCs        Breast                       Down-regulated                                         Yu et al. \[[@B32-jcm-08-00639]\] Ouzounova et al. \[[@B33-jcm-08-00639]\]

  **MiR-22**                 *TET2*                                                                                    Promotion of self- renewal and transformation                                   Hematological malignancies   Up-regulated                                           Song et al. \[[@B34-jcm-08-00639]\]

  **MiR-99**                 *Hoxa1*                                                                                   Regulation of self-renewal and multipotent differentiation capabilities         Hematological malignancies   Up-regulated                                           Khalaj et al. \[[@B35-jcm-08-00639]\]

  **MiR-126**                *PI3K/AKT/mTOR* pathway                                                                   Controller of cell cycle progression                                            Hematological malignancies   Up-regulated                                           Lechman et al. \[[@B36-jcm-08-00639]\]

  **MiR-150**                *Nanog*                                                                                   Suppression of proliferation and tumorigenicity of LSC                          Hematological malignancies   Down-regulated                                         Xu et al. \[[@B37-jcm-08-00639]\]

  **MiR-128**                *Bmi-1*                                                                                   Regulator of stem cell self-renewal                                             Glioblastoma                 Down-regulated                                         Godlewski et al. \[[@B39-jcm-08-00639]\]

  **MiR-451**                *PI3K/AKT*                                                                                Regulation of cell proliferation, invasion and apoptosis                        Glioblastoma                 Down-regulated                                         Gal et al. \[[@B40-jcm-08-00639]\]\
                                                                                                                                                                                                                                                                                           Nan et al. \[[@B41-jcm-08-00639]\]

  **MiR-34a**                *c-Met* and *Notch-1/2*                                                                   Tumor suppressor                                                                Glioblastoma                 Down-regulated                                         Guessous et al. \[[@B42-jcm-08-00639]\]

  **MiR-125b**               *E2F2*                                                                                    Regulation of cancer stem cell self-renewal and differentiation                 Glioblastoma                 Down-regulated                                         Wu et al. \[[@B43-jcm-08-00639]\]

  **MiR-29b**                *BCL2L2*                                                                                  Attenuates tumorigenicity and stemness maintenance                              Glioblastoma                 Down-regulated                                         Chung et al \[[@B44-jcm-08-00639]\].

  **MiR-200a**               *ZEB2*                                                                                    Inhibition of EMT                                                               Liver                        Down-regulated                                         Wang et al \[[@B46-jcm-08-00639]\]

  **MiR-491**                *GIT-1/NF-kb*                                                                             Inhibition of EMT                                                               Liver                        Down-regulated                                         Yang et al. \[[@B56-jcm-08-00639]\]

  **let-7 b**                *Frizzled 4*                                                                              Reduces the proportion of cancer stem cells                                     Liver                        Down-regulated                                         Cai et al. \[[@B48-jcm-08-00639]\]

  **let-7 a**                *Wnt* pathway                                                                             Inhibition of EMT                                                               Liver                        Down-regulated                                         Jin et al. \[[@B49-jcm-08-00639]\]

  **MiR-217**                *DKK1*                                                                                    Regulation of the CSC-like phenotypes                                           Liver                        Up-regulated                                           Jiang et al. \[[@B50-jcm-08-00639]\]

  **MiR-452**                *SOX 7*                                                                                   Promotion of stem-like cells                                                    Liver                        Down-regulated                                         Zheng et al. \[[@B51-jcm-08-00639]\]

  **MiR-200b/c, MiR-203**    *BMI1*, *ZEB1*                                                                            Coordinately function for the suppression of the stem cell properties of CSCs   Colorectal                   Down-regulated                                         Mukohyama et al. \[[@B52-jcm-08-00639]\]

  **MiR-34a**                *Notch*                                                                                   Maintenance of CSCs                                                             Colorectal                   Down-regulated                                         Mukohyama et al. \[[@B52-jcm-08-00639]\]

  **MiR-137**                *MSI1 DCLK1 FMNL1 CDC42*                                                                  Enhances the stem cell properties of CSCs                                       Colorectal                   Up-regulated                                           Mukohyama et al. \[[@B52-jcm-08-00639]\]

  **MiR-221**                *PTEN p27*, *p57*                                                                                                                                                                                                                                             

  **MiR-508**                *ZEB1*, *BMI1*, and *SALL4*,                                                              Inhibits the CRC EMT and stemness process.                                      Colorectal                   Down-regulated                                         Yan et al. \[[@B53-jcm-08-00639]\]

  **MiR-320**                *Wnt/*beta-catenin signaling pathway                                                      Promotes cancer stem cell-like properties                                       Prostate                     Down-regulated                                         Hsieh et al. \[[@B57-jcm-08-00639]\]

  **MiR-141**                *CD44*, *EZH2* and *Rho GTPases*                                                          Suppresses tumor growth and metastasis                                          Prostate                     Down-regulated                                         Liu et al. \[[@B55-jcm-08-00639]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CSCs: cancer stem cells; BCSCs: CSCs from breast cancer; LSC: leukemia stem cells; CRC: colorectal cancer; EMT: epithelial to mesenchymal transition; MiR: microRNA.

jcm-08-00639-t002_Table 2

###### 

Gastric cancer markers used to characterize gastric cancer stem cells.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker(s) Expression   In Vitro Assay              Efficiency (%) ^a^                 In Vivo Assay                     Efficiency (%) ^b^                    Reference(s)
  ---------------------- --------------------------- ---------------------------------- --------------------------------- ------------------------------------- ----------------------------------------------
  **CD44^+^**            Spheroid colony formation   10 cells/well\                     Tumorigenicity\                   20,000--30,000 cells injected ^1^\    1\. Takaishi et al. \[[@B20-jcm-08-00639]\]\
                                                     NCI-N87, MKN-74, MKN-45 ^1^\       (SCID mice) ^1^\                  Skin\                                 2. Sun et al. \[[@B68-jcm-08-00639]\]
                                                     20 cells/well\                     (Nude mice) ^2^                   NCI-N87, MKN-74, MKN-45\              
                                                     Human gastric cancer tissues ^2^                                     (100% efficiency)\                    
                                                                                                                          Stomach\                              
                                                                                                                          MKN-45\                               
                                                                                                                          (100% efficiency)\                    
                                                                                                                          MKN-74\                               
                                                                                                                          (75% efficiency)\                     
                                                                                                                          NCI-N87\                              
                                                                                                                          (50% efficiency)\                     
                                                                                                                          10,000 cells\                         
                                                                                                                          injected ^2^\                         
                                                                                                                          Human gastric cancer tissues\         
                                                                                                                          (80% efficiency)                      

  **CD44^+^/CD24^+^**    Tumoroid sphere formation   100 cell/well\                     Tumorigenicity (NOD/SCID mice)    200 cells injected\                   Zhang et al. \[[@B69-jcm-08-00639]\]
                                                     AGS                                                                  AGS (50% efficiency)                  

  **CD44^+^/CD54^+^**    Spheroid formation          1 cell/well\                       Tumorigenicity (SCID/Nude mice)   1000 cells injected\                  Chen et al. \[[@B70-jcm-08-00639]\]
                                                     Human gastric cancer tissues\                                        Human gastric cancer tissues\         
                                                     10,000 cells/dish\                                                   (100% efficiency)\                    
                                                     Blood samples                                                        9000 cells from spheres injected\     
                                                                                                                          gastric cancer cells in circulation   

  **CD44^+^/CD26^+^**    Spheroid formation          ≤5 × 10^6^ cells/dish\             Tumorigenicity (NOD/SCID mice)    100 cells injected\                   Nishikawa et al. \[[@B71-jcm-08-00639]\]
                                                     MKN7, MKN28, MKN45, AZ521                                            Human gastric cancer tissues\         
                                                                                                                          (100% efficiency)                     

  **CD44^+^/EpCAM^+^**   Spheroid formation          1 cell/well\                       Tumorigenicity\                   500 cells injected\                   Han et al. \[[@B72-jcm-08-00639]\]
                                                     Human gastric cancer tissues       (Nude mice)                       Human gastric cancer tissues\         
                                                                                                                          (50% efficiency)                      

  **CD44v8--10+**        Spheroid formation          100 cells/dish\                    Tumorigenicity (NOD/SCID mice)    200 cells injected\                   Lau et al. \[[@B73-jcm-08-00639]\]
                                                     (35-mm)\                                                             (75% efficiency)                      
                                                     GC45, GC84\                                                                                                
                                                     xenograft tumors                                                                                           

  **CD71^−^**            Colony formation            500--1000 cells/dish (35-mm)\      Tumorigenicity (NOD/SCID mice)    100 cells injected\                   Ohkuma M. et al. \[[@B74-jcm-08-00639]\]
                                                     MKN-1                                                                (80% efficiency)                      

  **CD90^+^**            Spheroid formation          5000 cells/mL\                     Tumorigenicity\                   100 cells injected\                   Jiang et al. \[[@B75-jcm-08-00639]\]
                                                     Gastric primary tumor model        (Nude mice)                       High Tumorigenicity group\            
                                                                                                                          (100% efficiency)                     

  **CD133^+^**           Colony formation            1 cell/well\                       Tumorigenicity\                   10,000 cells injected\                Chen et al. \[[@B76-jcm-08-00639]\]
                                                     KATO-III                           (Nude mice)                       (100% efficiency)                     

  **ALDH1^+^**           Colony formation            20,000 cells/well\                 Tumorigenicity\                   100 cells injected\                   Katsuno et al. \[[@B77-jcm-08-00639]\]
                                                     OCUM2-LMN                          (Nude mice)                       (100% efficiency)                     

  **LGR5^+^**            Spheroid formation          10,000 cells/well\                 Tumorigenicity\                   10,000 cells injected\                Zhang et al. \[[@B78-jcm-08-00639]\]
                                                     MKN-45, MKN-28                     (Nude mice)                       MKN-45, MKN-28\                       
                                                                                                                          (100% efficiency)                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The most representative gastric cancer markers used to characterize gastric cancer stem cells. The markers listed have the ability to generate spheroid colony and demonstrable tumorigenicity capability. Efficiency was expressed as: (a) the minimum number of cells to generate spheroid colony; and (b) the minimum number of sorted cells injected to ensure at last 50% of tumorigenicity. SCID: severe combined immunodeficient mice; Nude mice: Balb/cA nu/nu female mice; NOD/SCID: non/obese diabetic/severe combined immunodeficient.

jcm-08-00639-t003_Table 3

###### 

List of downregulated miRNAs in gastric cancer stem cell.  Adjusted *p*-value \<  0.05 was considered as statistically significant.

  ID                                        Motif                                                                                 Adjusted *p*-Value   Functional Relevance in GC
  ----------------------------------------- ------------------------------------------------------------------------------------- -------------------- -------------------------------------------
  MiR-93                                    AGCACTT                                                                               0.017                OncomiR \[[@B92-jcm-08-00639]\]
  MiR-302A_MiR-302B_MiR-302C                Tumor suppressor \[[@B100-jcm-08-00639],[@B101-jcm-08-00639],[@B102-jcm-08-00639]\]                        
  MiR-302D                                  No data                                                                                                    
  MiR-372_MiR-373\_ MiR-520C                Tumor suppressor \[[@B79-jcm-08-00639]\]                                                                   
  MiR-520E_MiR-520A\_ MiR-520B \_MiR-520D   Tumor suppressor \[[@B103-jcm-08-00639]\]                                                                  
  MiR-526B                                  Tumor suppressor \[[@B104-jcm-08-00639]\]                                                                  
  MiR-149                                   GAGCCAG                                                                               0.030                Tumor suppressor \[[@B105-jcm-08-00639]\]
  MiR-9                                     ACCAAAG                                                                               0.030                Tumor suppressor \[[@B106-jcm-08-00639]\]
  MiR-219                                   GACAATC                                                                               0.031                Tumor suppressor \[[@B107-jcm-08-00639]\]
  MiR-193A_MiR-193B                         GGCCAGT                                                                               0.031                OncomiR \[[@B108-jcm-08-00639]\]
  MiR-492                                   CAGGTCC                                                                               0.031                No data
  MiR-142_5P                                ACTTTAT                                                                               0.031                Tumor suppressor \[[@B109-jcm-08-00639]\]
  MiR-192_MiR-215                           TAGGTCA                                                                               0.039                Tumor suppressor \[[@B110-jcm-08-00639]\]

If not indicated, the motif could target the 5' arm, the 3' arm or both. GC: Gastric cancer; MiR: microRNA; OncomiR: oncogenic microRNA.

jcm-08-00639-t004_Table 4

###### 

List of upregulated miRNAs in gastric cancer stem cells. *p*-value \< 0.05 was considered as statistically significant.

  ID         Motif     *p*-Value   Functional Relevance in GC
  ---------- --------- ----------- ----------------------------------
  MiR-9      TAGCTTT   0.007       OncomiR \[[@B112-jcm-08-00639]\]
  MiR-431    GCAAGAC   0.014       No data
  MiR-302A   CACGTTT   0.025       OncomiR \[[@B79-jcm-08-00639]\]
  MiR-517    TCTAGAG   0.040       No data

Motif could target the 5' arm, the 3' arm or both. GC: gastric cancer; MiR: microRNA; OncomiR: oncogenic microRNA.

[^1]: Contributed equally as last authors.
